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Predictors of limb loss despite a patent
endovascular-treated arterial segment
Mohammad Usman Nasir Khan, MBBS,a Purandath Lall, MBBS,a,b Linda M. Harris, MD,a
Maciej L. Dryjski, MD,a and Hasan H. Dosluoglu, MD,a,b Buffalo, NY
Objective: The goal of this study was to assess the frequency and predictors of major amputation with patent
endovascular-treated arterial segments (PETAS) in patients with critical limb ischemia.
Methods:The study included 358 consecutive patients (412 limbs) who underwent endovascular (236 limbs) or open (176
limbs) revascularizations for critical limb ischemia from June 2001 through May 2007. Patients with limb loss despite
PETAS were compared with the rest of the endovascular-treated group (EV-other, n  212) and with those who
underwent amputations with patent bypasses (APB).
Results: The EV group underwent 30 amputations (24 in PETAS, 6 in EV-other), and 37 occurred in the open group (14
in APB, 23 in open-other). Amputations occurring despite a patent revascularized segment constituted 38% of limb loss
in open and 80% in EV-treated patients (P  .001). Limb loss occurred earlier in the PETAS group (58% vs 30% <3
months). Primary indications for limb loss in the PETAS group were extensive tissue loss or limb dysfunction after radical
débridement of infection or gangrene (37%), recurrent infection (42%), and failure to reverse ischemia (21%). There were
more patients with diabetes in PETAS group (96%) than in the APB group (64%, P  .018). Diabetes, dialysis-
dependence, lower albumin level, gangrene, and infrapopliteal interventions were more likely in the PETAS group than
in the EV-other group. Multivariate analysis showed diabetes (odds ratio [OR], 3.15; 95% confidence interval [CI],
1.22-8.13, P  .018), gangrene (OR, 3.33; 95% CI, 1.43-7.75; P  .005), and infrapopliteal interventions (OR, 3.09;
95% CI, 1.38-6.94; P  .006), predicted limb loss with patent open or EV-treated segments, whereas dialysis-
dependence, peroneal artery-only runoff, albumin level <3 g/dL, location at the heel, and treatment type did not.
Conclusions: Amputation despite PETAS is the most common means of limb loss in patients undergoing endovascular
revascularization for limb salvage. It is likely the result of aggressive attempts at limb salvage and usually occurs <3
months after the intervention. Patients with diabetes and gangrene undergoing infrapopliteal interventions are at a
significantly high risk. Adjuncts to reduce tissue loss, preserve limb function, and prevent recurrent infection are needed
to prevent limb loss despite PETAS, especially in diabetic patients. ( J Vasc Surg 2009;49:1440-6.)Limb loss with patent bypass has been reported to
occur in 4% to 9% of patients.1-4 The relative incidence of
amputations performed with patent bypass is higher, at up
to 50%, in certain subgroups, including patients with end-
stage renal disease,5-7 diabetes mellitus,2,8 and those with
limited runoff.9,10 The causes of limb loss in patients de-
spite patent grafts have included extensive infection, poor
pedal runoff, failure to reverse ischemia at the site of tissue
loss, heel necrosis (4 cm), and forefoot gangrene, espe-
cially in patients with diabetes and end-stage renal disease,8
and primary amputation has been suggested in these pa-
tients.1,5,7,8 The adoption of complex endovascular inter-
ventions has allowed limb salvage attempts in higher-risk
patients who would otherwise not have been considered for
revascularization, making the decision for primary amputa-
tion more complex.11-14
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1440Although the adoption of an aggressive endovascular-
first approach for all comers with critical limb ischemia has
decreased the primary amputation rate from 15% to 4%,
accompanied by a decrease in limb loss in patients in whom
limb salvage was attempted,13 we have found that most
amputations occurred in patients with patent endovascular-
treated segments (PETAS), which other authors have also
described.15,16 Despite numerous reports on limb loss de-
spite patent bypass grafts, limb loss with PETAS has not
been emphasized. The goal of this study was to assess the
frequency and predictors of major amputation with PETAS
in patients with critical limb ischemia.
MATERIAL AND METHODS
All consecutive patients who presented to the Veterans’
Administration Western New York Healthcare System be-
tween June 1, 2001, and May 31, 2007, with critical limb
ischemia (Rutherford category 4 to 6)17 and who under-
went a technically successful infrainguinal revascularization
by endovascular or open bypass procedures were identi-
fied from our prospectively maintained database after we
received Institutional Review Board approval for the
study. The database recorded patient demographics, co-
morbidities, clinical presentation, noninvasive arterial studies,
TransAtlantic Inter-Society Consensus (TASC) classification
of the treated lesions,18 details of the procedures per-
formed, the most distal level of intervention, number of
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limb at the last follow-up.
A patent runoff vessel was defined as an infrapopliteal
vessel without a hemodynamically significant (50%) an-
giographic stenosis distal to the treated site, and the num-
ber of adequately patent runoff vessels (0 to 3) was calcu-
lated after all interventions were completed for that limb.
In-line flow was defined as reinstitution of uninterrupted
flow by at least one nondiseased infrapopliteal runoff vessel
(anterior tibial, posterior tibial, or peroneal artery) to the
foot after revascularization. If the only runoff vessel was the
peroneal artery, this was noted.
Patients who underwent supramalleolar amputations
were identified, and the patency of their endovascular-
treated segments or the bypass grafts was recorded. The 24
patients with limb loss despite a patent endovascular-
treated segment (PETAS group) were compared with the
212 remaining in the endovascular-treated group (EV-
other), with the 14 patients who underwent amputations
with patent bypasses (APB), and with the 23 bypass pa-
tients who had amputation due to other causes (open-
other).
All patients were monitored by clinical assessment and
by our vascular laboratory during the first postoperative
visit at 1 to 4 weeks, at 3 and 6 months, and every 6 months
thereafter for ankle-brachial index (ABI) measurements,
graft or stent velocities, and duplex imaging. Angiography
was performed when clinically indicated.
All patients with open wounds underwent very close
follow-up in our vascular surgery wound clinic until
wounds were completely healed. The time to complete
healing was recorded. Repeat sharp débridements were
performed as necessary. Enzymatic débridement was
used when deemed necessary. Various adjuncts, includ-
ing vacuum-assisted closure (VAC, Kinetic Concepts Inc, San
Antonio, Tex) and various skin or collagen tissue sub-
strates, were used when deemed appropriate by the
vascular surgeon. Patients were referred for hyperbaric
oxygen therapy when other modalities failed. Autolo-
gous skin grafts were used when an adequate wound base
was achieved.
The patency of the endovascular-treated segments was
routinely checked using duplex examination. An angio-
gram was performed when wound healing was not ob-
served, with the intention of performing additional inter-
ventions if needed. Additional endovascular or bypass
procedures were performed if limb salvage was thought to
be feasible.
The débridements were mostly performed immediately
after the revascularization procedure. Patients with exten-
sive infection in whom débridement was thought to result
in extensive tissue loss or who had systemic sepsis initially
underwent wound débridement, and revascularization (en-
dovascular or open) was attempted immediately after sepsis
was controlled. The 18 patients who had extensive foot
sepsis and did not have adequate foot for salvage under-
went primary guillotine amputation without a revascu-
larization attempt during the study period. In our hos-pital, patients who are bedridden, especially with flexion
contractures, are offered primary amputation without
revascularization.
All endovascular procedures were performed by vascu-
lar surgeons in the operating room using the OEC 9800
system (General Electric Medical Systems, Salt Lake
City, Utah). Most infrainguinal interventions were per-
formed by a contralateral femoral artery approach using
6F sheaths. Society for Vascular Surgery (SVS) reporting
standards for lower extremity arterial procedures were
followed.17
Data analysis was performed using SPSS 16.0 software
(SPSS Inc, Chicago, Ill). Kaplan-Meier analysis and the log-
rank test were used to compare groups for limb salvage
and overall survival rates. Demographic comparisons
were made using the two-tailed Fisher exact test for cate-
goric variables and by the t test for continuous variables.
Univariate analyses were performed for identifying factors
predicting limb loss, and multivariate analysis was per-
formed using Cox proportional regression to identify the
independent predictors of limb loss. Statistical significance
was set at P  .05.
RESULTS
The analysis included 358 patients (99.2% men, 412
limbs) with critical limb ischemia. There were 197 patients
(236 limbs) in the endovascular-treated group and 161
patients (176 limbs) in the open group. When compared
with the open group, the patients in the endovascular
group were significantly older (71.5 10.6 vs 69.1 11.0,
P .022), were more frequently diabetic (59.3% vs 48.3%,
P  .028), and had hyperlipidemia (66.1% vs 55.7%, P 
.04). There were more patients with gangrene (43.6% vs
34.1%, P  .053) and more had tissue loss at the heel
(14.4% vs 5.1%, P  .002) in the endovascular group as
well.
Comparison of endovascular vs open-treated patients.
In the endovascular group, 30 amputations were performed,
giving an overall limb salvage of 87.3%. In the open group, 37
amputations were performed, giving an overall limb salvage of
79.0%. The 36-month limb salvage rates by Kaplan-Meier
analysis were 81%  4% in the endovascular-treated patients
and75%4% in theopengroup (P .1). In the endovascular
group, 24 amputations occurred despite a patent endovascular-
treated segment (PETAS group), and six occurred due to
failed endovascular-treated segments. Of these amputa-
tions, 21 were below the knee and 3 were above the knee.
In the open group, 14 amputations occurred in patients
with patent bypasses (APB group), and 23 occurred in
patients with occluded grafts. Half of the amputations
with patent bypasses were below the knee. Amputations
occurring despite patent revascularized segments consti-
tuted 38% of limb loss in the open patients and 80% in
the endovascular-treated patients (P  .001).
PETAS vs EV-other. Primary causes for limb loss in
the PETAS group were extensive tissue loss and limb
dysfunction after radical débridement of infection or gan-
grene (37%), recurrent infection (42%), and failure to re-
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ination and noninvasive studies. Eight patients in the
PETAS group (33%) had a repeat angiogram, three of
whom underwent reintervention for restenosis or treat-
ment of runoff vessels at 1, 3, and 21months after the initial
intervention. One patient underwent a popliteal-posterior
tibial bypass 1 month after the endovascular intervention.
Although the patient had a patent graft and stented seg-
ments, recurrent infection resulted in a below knee ampu-
tation 7 months later. None of the other patients who lost
their limbs for failure to reverse ischemia were eligible for
a bypass procedure because of lack of target vessels (2
patients) or poor medical condition (2 patients). The
six patients who underwent amputation with occluded
endovascular-treated segments underwent an angiogram,
and thrombolysis was attempted without success in three
patients. The remaining patients had either advanced infec-
tion or ischemia, and no further revascularization was at-
tempted.
The comorbidities and demographic characteristics of pa-
tients in the PETAS group and all other patients in the endovas-
cular group are summarized in Table I. The PETAS patients
were more likely to have diabetes, dialysis-dependence,
gangrene, a history of contralateral amputation, and
Table I. Patients with limb loss despite a patent
endovascular-treated arterial segment compared with all
other endovascular-treated patients
Variable
EV-other
(n  212)
PETAS
(n  24) P
Age, mean  SD, y 71.9  10.5 68.0  11.1 .09
CAD, % 60 67 .661
Hypertension, % 63 76 .214
Diabetes, % 55 96 .001
CVD, % 26 13 .212
Hyperlipidemia, % 67 54 .255
COPD, % 24 8 .119
Active smoker, % 39 38 1.0
Ever smoked, % 92 96 1.0
Renal insufficiency, % 25 38 .217
Dialysis-dependent, % 7 21 .038
Contralateral amputation, % 3 29 .001
Albumin, mean  SD, g/dL 3.3  0.6 2.7  0.5 .001
Tissue loss (gangrene), % 75 (40) 96 (79) .001
Heel ulcer/gangrene, % 14 21 .356
Infrapopliteal, % 20 54 .001
Femoropopliteal, % 53 46 .678
Aortoiliac, % 27 0 .001
ABI, mean  SD
Preoperative 0.40  0.25 0.43  0.26 .593
Postoperative 0.82  0.20 0.83  0.26 .875
In-line flow, % 91 96 .687
Runoff vessels, mean  SD,
No. 1.5  0.8 1.4  0.6 .382
Peroneal runoff, % 17 38 .025
ABI, Ankle-brachial index; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; CVD, cerebrovascular disease; EV, endovas-
cular; PETAS, patent endovascular-treated arterial segment; SD, standard
deviation.lower preoperative albumin levels. Overall, 80% of theendovascular-treated patients had TASC C or D lesions,
with no difference between the PETAS group and the
EV-other group (76% vs 81%, P  .188). The mean pre-
operative and postoperative ABI values were similar be-
tween the PETAS and the EV-other groups (Table I).
Although in-line flow to the foot, mean number of runoff
vessels, and hindfoot tissue loss were similar, more infrap-
opliteal interventions were done in the PETAS group, and
the peroneal artery was the only runoff vessel to the foot in
more patients. In the PETAS group, limb loss occurred1
month postoperatively in 7 patients, between 1 and 3months
in 7 patients, between 3 and 12 months in 7 patients, and at
14, 17, and 21 months in the remaining 3 patients.
PETAS vs APB. The comorbidities and other charac-
teristics of patients in the PETAS group and the APB group
are compared in Table II. There were significantly more
patients with diabetes in the PETAS group than in the APB
group (96% vs 64%, P  .018). Although more distal
revascularizations were performed in the APB group than
in the PETAS group, this was not statistically significant
(79% vs 54%, P  .175). The mean preoperative and
postoperative ABIs and the number of runoff vessels were
similar between the PETAS and APB groups (Table II). In
the PETAS group, 88% of all the amputations were per-
Table II. Patients with limb loss despite patent
endovascular-treated segments compared with patients
who had amputations with patent bypasses
Variable
APB
(n  14)
PETAS
(n  24) P
Age, mean  SD, y 63.6  12.0 68.0  11.1 .254
CAD, % 57 67 .729
Hypertension, % 86 76 .160
Diabetes, % 64 96 .018
CVD, % 21 13 .650
Hyperlipidemia, % 43 54 .737
COPD, % 14 8 .616
Active smoker, % 64 38 .179
Ever smoked, % 86 96 .542
Renal insufficiency, % 50 38 .510
Dialysis-dependent, % 21 21 .999
Contralateral amputation, % 14 29 .438
Albumin, mean  SD, g/dL 3.0  0.8 2.7  0.5 .321
Tissue loss (gangrene), % 86 (71) 96 (79) .392
Heel ulcer/gangrene, % 7 21 .383
Infrapopliteal, % 79 54 .175
Femoropopliteal, % 14 46 .077
Aortoiliac, % 7 0 .368
ABI, mean  SD
Preoperative 0.39  0.22 0.43  0.26 .679
Postoperative 0.84  0.25 0.83  0.26 .944
In-line flow, % 93 96 .615
Runoff vessels, mean  SD,
No. 1.2  0.6 1.4  0.6 .450
Peroneal runoff, % 21 38 .472
ABI, Ankle-brachial index; APB, amputation with patent bypass; CAD,
coronary artery disease; CVD, cerebrovascular disease; COPD, chronic
obstructive pulmonary disease; PETAS, patent endovascular-treated arterial
segment; SD, standard deviation.formed below the knee, whereas this was 50% in the APB
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group were extensive tissue loss or limb dysfunction after
radical débridement of infection or gangrene (7%), recur-
rent infection (21%), failure to reverse ischemia (50%), and
prosthetic graft infection (21%), which were significantly
different from PETAS group (P  .009).
All patients underwent duplex examination and nonin-
vasive studies, and graft patency was confirmed. Graft oc-
clusion in two patients was successfully treated using
thrombolysis at and 9 months before the amputation.
Angiograms in two additional patients were not able to
identify a correctable lesion. Limb loss occurred1 month
postoperatively in 1 patient, between 1 and 3 months in 4
patients, between 3 and 12 months in 7 patients, and at 38
and 46 months in the remaining 2 patients. Limb loss
occurred earlier in the PETAS group (58% vs 36% 3
months, P  .313). Most amputations occurred 12
months in both groups (PETAS, 88%; APB, 86%).
The 12-month survival rate in the PETAS group was
worse than in the EV-other (67% 10% vs 78% 3%, P
.065) and APB groups (86%  9%, P  .113), but these
rates were not statistically different owing to the small
number of patients in each group.
Predictors of PETAS/APB. Multivariate analysis
showed diabetes (odds ratio [OR], 3.15; 95% confidence
interval [CI], 1.22-8.13, P  .018), gangrene (OR, 3.33;
95% CI, 1.43-7.75; P .005), and infrapopliteal interven-
tions (OR, 3.09; 95% CI, 1.38-6.94; P  .006) predicted
limb loss with patent open or endovascular-treated seg-
ments, whereas dialysis-dependence, peroneal artery-only
runoff, albumin level 3 g/dL, location at the heel, and
type of treatment did not (Table III). However, the 12-
month limb salvage rate in the 26 patients with diabetes and
gangrene after infrapopliteal endovascular interventions
was 61%  11%, and 12-month survival was 64%  10%.
Nine of the 10 amputations in this subgroup occurred
despite PETAS. On the other hand, the 12-month limb
salvage rate in open-treated diabetic patients with gangrene
who underwent infrapopliteal bypasses was 58% 8% (P
.865 vs endovascular), and the 12-month survival was
Table III. Multivariate analysis of factors that predict
limb loss with patent open or endovascular-treated
segments
Factor OR 95% CI P
Diabetes 3.15 1.22-8.13 .018
Dialysis-dependence 2.24 0.85-5.91 .103
Albumin 3 g/dL 1.78 0.83-3.88 .142
Peroneal-only runoff 1.25 0.56-2.75 .588
Gangrene 3.33 1.43-7.75 .005
Open vs endovascular 1.85 0.81-4.21 .144
Infrapopliteal 3.09 1.38-6.94 .006
Heel location 1.87 0.61-5.79 .275
CI, Confidence interval; OR, odds ratio.71%  7% (P  .295 vs endovascular).DISCUSSION
Limb loss with patent bypass grafts is well-documented
and is generally a reflection of the vascular surgeon’s thresh-
old for attempting limb salvage in patients with adverse
features such as end-stage renal disease, diabetes, extensive
tissue loss, advanced infection, and poor functional status.
As the incidence of primary amputation decreases, the
chances of having limb loss with patent revascularization
increases.
The incidence of limb loss with patent bypass has varied
from 3%19 to as high as 59%,6 depending on the group
being studied; however, not all of these studies with high
limb loss described the at-risk patient subgroups. Carsten et
al4 reported 17 limb losses with patent grafts (57%), and
found that black race, renal failure, and infrapopliteal by-
passes were independently associated with this occurrence,
but diabetes was not. Seeger et al3 reported that limb loss
with a patent graft occurred in 46% of patients, which
constituted the largest subgroup of patients with limb loss,
and found that diabetes, extensive tissue loss, dialysis-
dependence, and poor runoff were predictors of this occur-
rence. Other reports of patients with critical limb ischemia
and dialysis-dependence also reported a high incidence of
up to 59% and also reported heel necrosis4 cm, diabetes,
extensive tissue loss, infection, and poor runoff were signif-
icant contributory factors for predicting limb loss with
patent grafts.5-7,20
We found that the incidence and other characteristics
of our open-treated group with patent grafts who had limb
loss were not too dissimilar from those reporting aggressive
limb salvage attempts.3,4 The relative incidence of limb loss
with patent grafts constituted 38% of all amputations in this
subgroup, and the clinical characteristics of this group were
similar to previous reports, with diabetes, 64%; end-stage
renal disease, 21%; undergoing infrapopliteal revasculariza-
tions, 79%; peroneal artery-only runoff, 21%; presenting
with gangrene, 71% (Table II). The incidence of limb
loss with PETAS was significantly higher (80%) in the
endovascular-treated group, however, possibly reflecting an
even more aggressive approach used in this subgroup of
patients, although the relative incidence of limb loss was
somewhat less than in the open-treated patients. Signifi-
cantly more diabetic patients were in the PETAS group
(96%) than in the APB group, and gangrene, contralateral
amputation, peroneal-only runoff, and heel location were
also more frequent in PETAS group. All these observations
suggest that patients with disadvantaged anatomic and
physiologic features were more likely to be offered endo-
vascular interventions rather than open interventions, re-
sulting in an increased incidence of limb loss with PETAS.
Another reason for the excessive occurrence of limb
loss with PETAS is the result of attempting limb salvage in
patients who would otherwise undergo primary amputa-
tion. Abou-Zamzam et al21 recently analyzed the risk fac-
tors that led to primary amputations vs limb salvage at-
tempts in 224 consecutive patients who presented with
critical limb ischemia. Major tissue loss, end-stage renal
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ated with primary amputation, which occurred in 43% of
their patients. These risk factors are similar to ours and
other reports1-4 that predict limb loss with patent revascu-
larized extremities. This suggests that as the primary ampu-
tation rate increases, there will be less limb loss with patent
revascularized extremities, and vice versa. We have previ-
ously reported13 that adoption of endovascular interven-
tions has resulted in a decreased rate of primary amputation
from 15% to 4% in addition to increased limb salvage in
those with attempted limb salvage. Our observation that
most endovascular-treated patients had limb loss despite
PETAS is likely a direct reflection of this change in practice
and our overall increased aggressiveness of limb salvage
attempt in higher risk patients. Interestingly, the overall
number of limbs lost actually was less in the endovascular-
treated group as a whole, and the increased aggressiveness
resulted in a better limb salvage rate than the open group
despite worse clinical characteristics.
The risk factors that were associated with limb loss
despite PETAS and open-treated patients were diabetes,
gangrene, and infrapopliteal interventions in the multivar-
iate analysis. We also found that patients with end-stage
renal disease, peroneal-only runoff, and contralateral am-
putations were significantly more in PETAS group than the
remainder of the endovascular-treated patients. These find-
ings are similar to the previous reports on limb loss with
patent grafts.3-5 We also found several other factors that
were common, including contralateral amputation, poor
nutritional status, and peroneal-only runoff in patients with
limb loss despite PETAS. Although nonsignificant in our
series, contralateral amputation as an independent predic-
tor has been reported, with a 20% to 24% incidence of
contralateral amputation in patients with limb loss,1,2,22
and is likely a reflection of the overall poor general condi-
tion of these patients. The peroneal artery as the only runoff
has been reported as being adequate after open and endo-
vascular revascularizations for limb salvage23-26 andwas not
associated with limb loss despite a patent revascularized
segment in the multivariate analysis in our series.
The timing of limb loss with patent revascularized
extremities seems to be similar in our study as in those
reporting on bypasses.1-4 In our PETAS group, 58% of the
limb loss occurred 3 months, and 79% were infection-
related. Patients requiring early amputation had over-
whelming infection that resulted in extensive tissue loss
despite repeated débridements in an attempt to control
infection. Late infection-related amputations were mostly
in diabetic patients with recurrent infections in a refractory
wound, despite adequate perfusion and aggressive wound
care. In the series by Carsten et al,4 53% of amputations
despite patent grafts occurred30 days and the remaining
after 45 days. In other series, 50% to 66% of such amputa-
tions occurred early, mainly due to infections,3,5,6 with a
few cause by poor runoff resulting in failure to reverse
ischemia at the tissue level.
Although selection of patients before attempting revas-
cularization is an attractive idea,27 our study fails to identifyspecific parameters that would predict limb loss and allow
us to recommend primary amputation in a subset of pa-
tients. In fact, we found that limb salvage was achieved in
61% of patients in the endovascular group and in 58% in the
open-treated groups in whom all three predictors of limb
loss with patent revascularized limbs were identified in the
multivariate analysis. Our results, however, prompt us to
recommend careful patient selection for revascularization,
especially among those with diabetes mellitus, gangrene,
and significant infrapopliteal disease.
Infection seems to be a significant cause of early limb
loss despite revascularization; thus, one could argue that
revascularization should be considered after adequate
débridement and infection control, which might possibly
select out those with advanced infections and nonsalvage-
able limbs. Because the endovascular interventions allow
revascularization with remote access sites and the risk of
infection of the endovascular-treated segment, even in the
face of pedal infection is extremely low, angiograms with
attempted endovascular interventions will continue to be
used by aggressive vascular surgeons and other interven-
tionalists. Better assessment of the extent of infection and
improvements in postoperative wound care and control of
infection may potentially decrease the rate of early limb loss
despite patent revascularized extremities.6
Survival of patients who had limb loss with PETAS was
marginally worse than the rest of the endovascular-treated
patients, which was likely a reflection of the poorer medical
condition of this subgroup or was possibly due to the
negative effect of amputation on survival in some patients.
In the Reifsnyder et al1 series of 67 patients who underwent
major amputations after bypass procedures, the 2-year sur-
vival of 21% was much worse than our rates of 56% in
PETAS and 57% in the APB groups. We do not think that
attempting limb salvage in these patients had a negative
effect on their survival.
Another potential advantage of an aggressive endovas-
cular approach is the possibility that the revascularization
may have enabled the amputation to be performed at a
more distal level for the PETAS group. In our series, 88% of
the amputations were below the knee in the PETAS group,
whereas this was only 50% in the APB group (P  .021).
Our study has certain limitations, including the retro-
spective nature and the small sample size treated by a single
vascular surgeon in a single center with a nearly all male
population. In addition, we do not have any objective
information of the skin perfusion pressure or transcutane-
ous oxygen pressure, and pedal angiography was not rou-
tine in all patients because of concerns about contrast use or
patient movement.
CONCLUSIONS
Aggressive use of endovascular interventions has re-
sulted in limb salvage attempts in higher-risk patients who
would otherwise have primary amputations. This resulted
in amputations despite PETAS being the most common
means of limb loss in patients undergoing endovascular
revascularization for limb salvage. This occurs mostly in the
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and gangrene who undergo infrapopliteal interventions are
at significantly higher risk. Adjuncts to reduce tissue loss,
preserve limb function, and prevent recurrent infection are
needed to prevent limb loss despite PETAS, especially in
diabetic patients.
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Kahn and associates have made the observation that amputa-
tion with a patent intervention or bypass performed for critical
limb ischemia occurred in nearly 40% of the patients losing limbs
after arterial bypass surgery and in an astounding 80% of those
having amputation after a catheter-based intervention. They at-
tribute these findings to having adopted an “endovascular first”l Deaconess Medical Center, Boston, Mass
wards limb salvage attempt even in marginal situations. They base
this approach on two assumptions:
The physiological insult to the patient treated with endovas-
cular therapy is far less than bypass surgery, so why not try it in
marginal situations?
There are no objective clinical criteria that can reliably predict the
likelihoodof limb salvage or limb loss in all patients prior to treatment.
